Post R M, Nolen W A, Kupka R W, Denicoff K D, Leverich G S, Keck P E, McElroy S L, Rush A J, Suppes T, Altshuler L L, Frye M A, Grunze H, Walden J
National Institute of Mental Health, Bethesda, Maryland, USA.
Br J Psychiatry Suppl. 2001 Jun;41:s169-76. doi: 10.1192/bjp.178.41.s169.
The Stanley Foundation Bipolar Network (SFBN) was created to address the paucity of help studies in bipolar illness.
To describe the rationale and methods of the SFBN.
The SFBN includes five core sites and a number of affiliated sites that have adopted consistent methodology for continuous longitudinal monitoring of patients. Open and controlled studies are performed as patients' symptomatology dictates.
The reliability of SFBN raters and the validity of the rating instruments have been established. More than 500 patients are in continuous daily longitudinal follow-up. More than 125 have been randomised to one of three of the newer antidepressants (bupropion, sertraline and venlafaxine) as adjuncts in a study of mood stabilizers and 93 to omega-3 fatty acids. A number of open clinical case series have been published.
Well-characterised patients are followed in a detailed continuous longitudinal fashion in both opportunistic case series and double-blind, randomised controlled trials with reliable and validated measures.
斯坦利基金会双相情感障碍网络（SFBN）的设立是为了解决双相情感障碍相关研究的匮乏问题。
描述SFBN的基本原理和方法。
SFBN包括五个核心站点和一些附属站点，这些站点采用一致的方法对患者进行持续的纵向监测。根据患者的症状表现开展开放和对照研究。
已确立SFBN评估者的可靠性和评估工具的有效性。超过500名患者接受每日持续纵向随访。在一项心境稳定剂研究中，超过125名患者被随机分配至三种新型抗抑郁药（安非他酮、舍曲林和文拉法辛）之一作为辅助用药，93名患者被随机分配至ω-3脂肪酸组。已发表了一些开放临床病例系列。
在机会性病例系列研究以及双盲随机对照试验中，采用可靠且经过验证的测量方法，以详细的持续纵向方式对特征明确的患者进行随访。
